(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Exhibit No. | Description | |||||||
99.1 | ||||||||
104.1 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
ZOSANO PHARMA CORPORATION | |||||||||||||||||
Date: March 17, 2022 | By: | /s/ Christine Matthews | |||||||||||||||
Name: Christine Matthews | |||||||||||||||||
Title: Chief Financial Officer |
Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||||||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||||||||||||||||||||||||||
(unaudited) | (unaudited) | ||||||||||||||||||||||||||||||||||||||||||||||
Service revenue | $ | 87 | $ | 224 | $ | 785 | $ | 224 | |||||||||||||||||||||||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||
Cost of service revenue | 92 | 171 | 796 | 171 | |||||||||||||||||||||||||||||||||||||||||||
Research and development | 4,659 | 5,352 | 20,974 | 21,622 | |||||||||||||||||||||||||||||||||||||||||||
General and administrative | 2,253 | 2,637 | 10,547 | 11,189 | |||||||||||||||||||||||||||||||||||||||||||
Total operating expenses | 7,004 | 8,160 | 32,317 | 32,982 | |||||||||||||||||||||||||||||||||||||||||||
Loss from operations | (6,917) | (7,936) | (31,532) | (32,758) | |||||||||||||||||||||||||||||||||||||||||||
Other income (expense): | |||||||||||||||||||||||||||||||||||||||||||||||
Interest income | 1 | 1 | 3 | 18 | |||||||||||||||||||||||||||||||||||||||||||
Interest expense | (53) | (158) | (189) | (719) | |||||||||||||||||||||||||||||||||||||||||||
Other income (expense), net | (2) | (5) | 1,793 | 90 | |||||||||||||||||||||||||||||||||||||||||||
Loss before provision for income taxes | (6,971) | (8,098) | (29,925) | (33,369) | |||||||||||||||||||||||||||||||||||||||||||
Provision for income taxes | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||
Net loss | $ | (6,971) | $ | (8,098) | $ | (29,925) | $ | (33,369) | |||||||||||||||||||||||||||||||||||||||
Net loss per common share – basic and diluted | $ | (0.06) | $ | (0.08) | $ | (0.27) | $ | (0.49) | |||||||||||||||||||||||||||||||||||||||
Weighted-average common shares used in computing net loss per common share – basic and diluted | 118,991 | 102,066 | 112,064 | 67,907 |
December 31, 2021 | December 31, 2020 | ||||||||||||||||||||||
ASSETS | |||||||||||||||||||||||
Current assets: | |||||||||||||||||||||||
Cash and cash equivalents | $ | 11,043 | $ | 35,263 | |||||||||||||||||||
Accounts receivable | 146 | — | |||||||||||||||||||||
Prepaid expenses and other current assets | 420 | 453 | |||||||||||||||||||||
Total current assets | 11,609 | 35,716 | |||||||||||||||||||||
Restricted cash | 455 | 455 | |||||||||||||||||||||
Property and equipment, net | 32,557 | 30,909 | |||||||||||||||||||||
Operating lease right-of-use assets | 3,769 | 4,928 | |||||||||||||||||||||
Other long-term assets | — | 3 | |||||||||||||||||||||
Total assets | $ | 48,390 | $ | 72,011 | |||||||||||||||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||||||||||||
Current liabilities: | |||||||||||||||||||||||
Accounts payable | $ | 2,120 | $ | 1,884 | |||||||||||||||||||
Accrued compensation | 1,767 | 2,294 | |||||||||||||||||||||
Build-to-suit obligation, current portion, net of debt issuance costs and discount | 3,822 | 4,779 | |||||||||||||||||||||
Operating lease liabilities, current portion | 1,606 | 1,378 | |||||||||||||||||||||
Paycheck Protection Program loan, current portion | — | 809 | |||||||||||||||||||||
Other accrued liabilities | 1,818 | 3,367 | |||||||||||||||||||||
Total current liabilities | 11,133 | 14,511 | |||||||||||||||||||||
Build-to-suit obligation, long-term portion, net of debt issuance costs and discount | 970 | 4,359 | |||||||||||||||||||||
Operating lease liabilities, long-term portion | 3,081 | 4,687 | |||||||||||||||||||||
Paycheck Protection Program loan, long-term portion | — | 812 | |||||||||||||||||||||
Other long-term liabilities | 231 | 127 | |||||||||||||||||||||
Total liabilities | 15,415 | 24,496 | |||||||||||||||||||||
Stockholders’ equity: | |||||||||||||||||||||||
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of December 31, 2021 and 2020 | — | — | |||||||||||||||||||||
Common stock, $0.0001 par value; 250,000,000 shares authorized as of December 31, 2021 and 2020; 120,205,813 and 102,066,218 shares issued and outstanding as of December 31, 2021 and 2020, respectively | 12 | 10 | |||||||||||||||||||||
Additional paid-in capital | 395,078 | 379,695 | |||||||||||||||||||||
Accumulated deficit | (362,115) | (332,190) | |||||||||||||||||||||
Total stockholders’ equity | 32,975 | 47,515 | |||||||||||||||||||||
Total liabilities and stockholders’ equity | $ | 48,390 | $ | 72,011 |
Cover Page |
Mar. 11, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Mar. 17, 2022 |
Entity Registrant Name | ZOSANO PHARMA CORPORATION |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-36570 |
Entity Tax Identification Number | 45-4488360 |
Entity Address, Address Line One | 34790 Ardentech Court |
Entity Address, City or Town | Fremont |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94555 |
City Area Code | 510 |
Local Phone Number | 745-1200 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value |
Trading Symbol | ZSAN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Flag | false |
Entity Central Index Key | 0001587221 |
6 -!RE=LSG3?Z6!@I95JD0\82+C4A#%5G D(GP&LK\,S4-AB.G8RF
M2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&3K;V"%TH
M?653#@%%G=W4Q7/4 6_*P>-HK(0* Y1OJA65UY**+2?=T>M,[Q\FCUI&Z]Q*
MN??P2K8<RHY_U=3_ 102P,$% @ W8!Q5)>*NQS $P( L !?
050CC^H08W>-DME>S=YI\9]+23 =)
M+0GWDJRY7!E$/3XVQ1-OMQM',? ]UF]$"Y@8[(L3\@[#V 2Z?"JB56!#BN9<
M"D\<]I0EDA;8Q7!UPG'2Q"H&99+XQR!T15K^ 2[&N*0DN?0('OW PH.GW\S@,84H(%8)%F0_RR\]F;UEY4$V&636;
MN9X-*M2I20[^POZ*.?CP,#W+OTE[+1(%.=3T%1HH?^E(P]#T6O:-%EX<= :I
M?),V2H;+*<-9=O:CWM9#9*N&
M]Z"F#4*2IK$!MZK
E%BQP[+<.I/0IXWI0K^.UR[2'/#2N"2=80;0-%71S%
MTEL*+,=E9(P%:_5PB>2+W5Y8%&/'XIDZCH*!"W=]&E&K,I6W&Y;/@2CI3+0$
MN+.X,@8@EB9#O$J!@9$QL>& ^(X3O>A08Z=C"(5'@